Comparing antibody combinations after stem cell transplant for multiple myeloma
Treatments studied
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy clinical trials.
This study tests whether a combination of two new antibody drugs (teclistamab and talquetamab) works better than the standard combination (daratumumab and lenalidomide) for patients who still have minimal myeloma left after a stem cell transplant. The goal is to see if the new treatment can completely eliminate the remaining cancer cells and improve long-term outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have multiple myeloma and have already received a stem cell transplant using your own cells.
- Even after the transplant, a very sensitive test still finds a small number of myeloma cells in your bone marrow.
- It has been less than 6 months since your transplant, or up to 7 months if you had extra treatment after it.
- You are at least 18 years old and able to do your daily activities with some help if needed.
- Your liver and kidney function are within acceptable limits.
- You do not have poorly controlled heart, lung, or nervous system conditions.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of immunotherapy drugs for patients with newly diagnosed, high-risk multiple myeloma. The goal is to see if this multi-target approach can improve outcomes by using the immune system to attack the cancer.
This trial compares two approaches after initial therapy for newly diagnosed multiple myeloma: a T-cell engager (elranatamab) versus a stem cell transplant. The goal is to see which provides better control of the disease, using sensitive MRD testing to guide further treatment.
This trial is testing a new combination of drugs for people with untreated multiple myeloma who are healthy enough for a stem cell transplant. It aims to see if the treatment is safe and effective.
This trial compares two different combinations of medications for people with newly diagnosed multiple myeloma who are not planning to have a stem cell transplant. It looks at whether adding a targeted antibody drug is as effective as the standard approach.
This trial tests combining two drugs, talquetamab and lenalidomide, as maintenance therapy after a stem cell transplant for multiple myeloma. The goal is to see if this combination helps keep the cancer from coming back.
This phase 3 trial tests two different drug combinations to treat newly diagnosed multiple myeloma. It may help by aiming to control the cancer without using high-dose chemotherapy and stem cell transplant for people who can’t receive that approach.
Hear when a new Multiple Myeloma (MM) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.